TNGX TANGO THERAPEUTICS INC

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

BOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 10 at 3:20-3:55 PM ET.

The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit

Investors and Media:

Elizabeth Hickin



EN
27/05/2025

Underlying

TNGXTANGO THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TANGO THERAPEUTICS INC

 PRESS RELEASE
Free
TNGX TANGO THERAPEUT...

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Glo...

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference BOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 10 at 3:20-3:55 PM ET. The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the ...

May 27, 2025 1 EN
 PRESS RELEASE
Free
TNGX TANGO THERAPEUT...

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 T...

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the TNG456 Phase 1/2 trial in patients with MTAP-deleted solid tumors, with a focus on glioblastoma (GBM). TNG456 is a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor. “Dosing the ...

May 21, 2025 1 EN
 PRESS RELEASE
Free
TNGX TANGO THERAPEUT...

Tango Therapeutics Reports First Quarter 2025 Financial Results and Pr...

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights – Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 – – Cash position of $217 million as of March 31, 2025; cash runway extended into 1Q 2027 with reduction of preclinical spend –   BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation...

May 12, 2025 1 EN
 PRESS RELEASE
Free
TNGX TANGO THERAPEUT...

Tango Therapeutics to Report First Quarter 2025 Financial Results on M...

Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an appr...

May 1, 2025 1 EN
 PRESS RELEASE
Free
TNGX TANGO THERAPEUT...

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology...

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been accepted as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois....

March 25, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch